var title_f9_34_9760="Antibody elution technique";
var content_f9_34_9760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F53831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F53831&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Antibody elution technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 367px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9760=[""].join("\n");
var outline_f9_34_9760=null;
var title_f9_34_9761="Fenbufen: International drug information";
var content_f9_34_9761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenbufen: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Afiancen (AR);",
"     </li>",
"     <li>",
"      Bifene (PT);",
"     </li>",
"     <li>",
"      Cincopal (ES);",
"     </li>",
"     <li>",
"      Cinopal (DK);",
"     </li>",
"     <li>",
"      Lederfen (AT, GB, LU);",
"     </li>",
"     <li>",
"      Reugast (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Nonsteroidal Anti-inflammatory Drug",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of pain and inflammation in rheumatic disease and other musculoskeletal disorders",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Children &lt;14 years: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Adults: 300 mg in the morning and 600 mg at bedtime or 450 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Capsule: 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 300 mg, 450 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10384 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-519069B3B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9761=[""].join("\n");
var outline_f9_34_9761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303439\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978837\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978840\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978836\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821066\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978839\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10384|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_34_9762="Penetrating duodenal ulcer on fluoroscopy";
var content_f9_34_9762=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Penetrating duodenal ulcer on fluoroscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 366px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Air contrast upper gastrointestinal series demonstrating an ulcer involving the duodenal bulb. The ulcer was found to penetrate into the pancreas (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of J Pierre Sasson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9762=[""].join("\n");
var outline_f9_34_9762=null;
var title_f9_34_9763="DEB squamous cell carcinoma 2";
var content_f9_34_9763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Squamous cell carcinoma in severe generalized recessive epidermolysis bullosa (EB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Squamous cell carcinoma on the elbow of a patient with severe, generalized recessive dystrophic EB. Clinically, squamous cell carcinoma may masquerade as a nonhealing wound. Although histopathology is often well-differentiated, the tumor is often extremely aggressive.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9763=[""].join("\n");
var outline_f9_34_9763=null;
var title_f9_34_9764="Ivermectin (topical): Patient drug information";
var content_f9_34_9764=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ivermectin (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/16/1283?source=see_link\">",
"     see \"Ivermectin (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/53/37714?source=see_link\">",
"     see \"Ivermectin (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14699482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Sklice&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13854449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat head lice.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13854448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ivermectin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13854453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13854454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697982",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching. Talk to the doctor about what to do.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13854456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If live lice are seen after 7 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13854451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696964",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to use carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3069424",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your scalp and hair only. Keep out of your mouth, nose, ears, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694807",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not wet hair before putting on lotion.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668610",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rub into dry hair and scalp all the way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696254",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leave on your hair and scalp for 10 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668612",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After 10 minutes, fully rinse hair and scalp with water only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use special nit comb or tweezers to get rid of dead nits (lice eggs) from hair.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696239",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash all bedding, towels, and recently worn clothes in hot water or have them dry cleaned.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash all combs, brushes, and hair clips in hot water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13854452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13854457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away any part not used after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13854458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83355 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-C1F21EE0D5-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9764=[""].join("\n");
var outline_f9_34_9764=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14699482\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854449\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854448\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854453\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854454\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854456\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854451\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854452\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854457\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854458\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/42/40613?source=related_link\">",
"      Ivermectin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/43/12980?source=related_link\">",
"      Ivermectin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/49/33557?source=related_link\">",
"      Ivermectin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/16/1283?source=related_link\">",
"      Ivermectin (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/53/37714?source=related_link\">",
"      Ivermectin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_34_9765="gottrons sign a";
var content_f9_34_9765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51110&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Gottron's sign in a patient with amyopathic dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 336px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; 2012 American College of Rheumatology. Used with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9765=[""].join("\n");
var outline_f9_34_9765=null;
var title_f9_34_9766="Flunisolide (oral inhalation): Drug information";
var content_f9_34_9766=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Flunisolide (oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/49/34581?source=see_link\">",
"    see \"Flunisolide (oral inhalation): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8097083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aerospan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8097139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Inhalant (Oral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8097240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral Inhalation: 160 mcg twice daily (morning and evening); maximum dose: 320 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 320 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;320-640 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;640 mcg daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8097239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Oral inhalation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-11 years: 80 mcg twice daily (morning and evening); maximum dose: 160 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines (NIH, 2007)",
"     </i>",
"     (administer in divided doses twice daily):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 160 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: 320 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &ge;640 mcg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8097241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15403958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, accumulation not expected to be significant given the rapid and extensive metabolism to less active metabolites and minimal urinary excretion.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15403959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Flunisolide is metabolized hepatically; however, systemic absorption may not be clinically significant and accumulation in hepatic impairment is expected to be minimal.",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8097125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15589658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aerospan&reg;: FDA approved September 2012; availability anticipated for Fall of 2013.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F8097266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Shake well before using. Prime inhaler prior to first use and when the inhaler has not been used for &gt;2 weeks by releasing 2 test sprays away from the face. Rinse mouth following use of oral inhalers. Do not immerse the canister into water to determine remaining amount in the canister (ie, &ldquo;float test&rdquo;).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8097147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maintenance treatment and prophylactic therapy for asthma; to reduce or eliminate the need for oral corticosteroids in steroid-dependent asthma patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8097074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Flunisolide may be confused with Flumadine&reg;, fluocinonide",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8097189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (9% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (17% to 18%), rhinitis (4% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (1% to 3%), edema (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (1% to 7%), pain (2% to 5%), dizziness (1% to 3%), insomnia (1% to 3%), migraine (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 4%), erythema multiforme (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (&le;5%), dyspepsia (2% to 4%), abdominal pain (1% to 3%), diarrhea (1% to 3%), gastroenteritis (1% to 3%), nausea (1% to 3%), oral moniliasis (1% to 3%), taste perversion (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (1% to 4%), vaginitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (1% to 3%), myalgia (1% to 3%), neck pain (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Conjunctivitis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ear pain (1% to 3)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (4% to 9%), cough increased (2% to 9%), bronchitis (1% to 3%), laryngitis (1% to 3%), epistaxis (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction (4% to 5%), bacterial infection (1% to 4%), infection (1% to 3%), voice alteration (1% to 3%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8097151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to flunisolide or any component of the formulation; acute status asthmaticus or other acute asthma episodes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8097152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children, in patients receiving high doses for prolonged periods, or when used with inhaled or systemic corticosteroids (even alternate-day dosing). HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly, carefully, and may require several months. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic effects needed to treat patients having trauma, surgery, or infections. Do",
"     <b>",
"      not",
"     </b>",
"     use flunisolide to transfer patients from oral corticosteroid therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: May occur with wheezing after inhalation;  if this occurs, treat with a fast-acting bronchodilator. Stop flunisolide therapy and select an alternative agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Exposure to chickenpox and measles should be avoided; use with caution in patients with ocular herpes simplex. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use. Consider routine eye exams in chronic users.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8097194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8097195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8097148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8097149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and fetotoxic effects were observed in animal studies. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma (most information available using budesonide) during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8097150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9770301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other corticosteroids have been found in breast milk. It is not known if sufficient quantities of flunisolide are absorbed following inhalation to produce detectable amounts in breast milk. The use of inhaled corticosteroids is not considered a contraindication to breast-feeding.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8097201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases airway inflammation by suppression of endogenous inflammatory mediators (kinins, histamine, liposomal enzymes, prostaglandins). Inhibits inflammatory cell migration and reverses increased capillary permeability to decrease access of inflammatory cells to the site of inflammation; does not depress hypothalamus.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F8097231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Extensive; V",
"     <sub>",
"      d",
"     </sub>",
"     : 170-350 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Rapid and extensive hepatic metabolism via CYP3A4 to a minimally active metabolite (6 beta-OH flunisolide); also undergoes conjugation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: &lt;7%; Oral inhalation: ~34%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.3-1.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Within 5-10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Rapid; not detectable in plasma 12-hours post dose; urine (&lt;1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Dickens GR, Wermeling DP, Matheny CJ, et al, &ldquo;Pharmacokinetics of Flunisolide Administered Via Metered Dose Inhaler With and Without a Spacer Device and Following Oral Administration,&rdquo;",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2000, 84(5):528-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/34/9766/abstract-text/10831007/pubmed\" id=\"10831007\" target=\"_blank\">",
"        10831007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      NAEPP Working Group Report on &ldquo;Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment,&rdquo; National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 05-5236, March 2005. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/health/prof/lung/asthma/astpreg/astpreg_full.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Buck JJ, et al, \"Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate,\"",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2002, 19(6):1207-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/34/9766/abstract-text/12108877/pubmed\" id=\"12108877\" target=\"_blank\">",
"        12108877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Ross-Russell R, et al, \"Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom,\"",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2002, 87(6):457-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/34/9766/abstract-text/12456538/pubmed\" id=\"12456538\" target=\"_blank\">",
"        12456538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9126 Version 23.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9766=[""].join("\n");
var outline_f9_34_9766=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097083\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097139\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097240\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097239\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097241\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15403958\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15403959\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097125\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15589658\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097266\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097147\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097074\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097189\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097151\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097152\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097194\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097195\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097148\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097150\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770301\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097201\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8097231\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9126\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9126|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?29/62/30691?source=related_link\">",
"      Flunisolide (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/30/4580?source=related_link\">",
"      Flunisolide (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/24/22915?source=related_link\">",
"      Flunisolide (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/49/34581?source=related_link\">",
"      Flunisolide (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_34_9767="Lichen planopilaris";
var content_f9_34_9767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52848&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planopilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous, keratotic papules at the base of hair follicles and scarring alopecia are present on the scalp in this patient with lichen planopilaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9767=[""].join("\n");
var outline_f9_34_9767=null;
var title_f9_34_9768="Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy";
var content_f9_34_9768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Advanced non-small cell lung cancer: Maintenance therapy after initial chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/34/9768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9768/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/34/9768/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9768/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/34/9768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9768/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/34/9768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with lung cancer depends upon tumor stage, histology, molecular characteristics, and an assessment of the patient's overall medical condition.",
"   </p>",
"   <p>",
"    Patients with stage I, II, or III non-small cell lung cancer (NSCLC) (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ) are generally treated with curative intent using surgery, radiation therapy (RT), or a combined modality approach that includes adjuvant chemotherapy. In contrast, palliative systemic therapy is appropriate for patients who present with stage IV disease. Palliative systemic therapy is also used for patients who have relapsed with advanced disease following prior definitive treatment.",
"   </p>",
"   <p>",
"    For patients with advanced NSCLC, systemic therapy should be individualized based upon molecular and histologic features of the tumor. For patients whose tumor does not contain a driver mutation (eg, EGFR, ALK fusion oncogene), initial treatment generally is cytotoxic chemotherapy, which can prolong survival without significantly impairing quality of life. Cytotoxic chemotherapy is also used initially for patients in whom the mutation status of the tumor is not known.",
"   </p>",
"   <p>",
"    Continuing treatment with the initial chemotherapy combination indefinitely may improve progression-free survival but is associated with increased toxicity and does not have a clinically significant impact on overall survival. Thus, guidelines from the American Society of Clinical Oncology (ASCO) recommend discontinuing such treatment after four to six cycles [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Randomized trials have demonstrated that maintenance therapy with single agent chemotherapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ) or an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) prolongs progression-free survival and may prolong overall survival.",
"   </p>",
"   <p>",
"    The role of maintenance therapy with single agent chemotherapy agent or a molecularly targeted agent is reviewed here. Other relevant topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"       \"Overview of the treatment of advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"       \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848339707\">",
"    <span class=\"h1\">",
"     APPROACH TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who have an ongoing objective response or stable disease after four to six cycles of chemotherapy, the combination chemotherapy should be discontinued and maintenance therapy considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients whose tumor has a driver mutation and who have an objective response or stable disease after the initial combination chemotherapy, we suggest maintenance with either single agent chemotherapy or a targeted agent rather than with no therapy. There are no data directly comparing continuation of chemotherapy with a switch to a tyrosine kinase inhibitor. Factors that should be discussed with the patient in defining a treatment plan include the quality of the initial response to chemotherapy and the potential side effects of maintenance therapy.",
"     </li>",
"     <li>",
"      For patients without a driver mutation, both maintenance single agent chemotherapy and an EGFR TKI have been shown to increase progression free survival and may increase overall survival. Our approach generally is to use single agent maintenance chemotherapy in this setting, although treatment with an EGFR TKI or careful observation are alternatives. (See",
"      <a class=\"local\" href=\"#H1848338461\">",
"       'Patients without a driver mutation'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848338860\">",
"    <span class=\"h1\">",
"     PATIENTS WITH A DRIVER MUTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with advanced NSCLC who were initially treated with chemotherapy but in whom a driver mutation has subsequently been identified, continuation of therapy with an appropriate targeted agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"     crizotinib",
"    </a>",
"    ) after the initial chemotherapy is indicated.",
"   </p>",
"   <p>",
"    There are no randomized trials conducted in patients known to have an EGFR mutation or other driver mutation prior to the initiation of chemotherapy. However, analysis of outcomes based upon mutation status in a subset of patients in the SATURN trial provides evidence that maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    substantially improves progression free survival in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the SATURN trial, previously untreated patients with advanced NSCLC were treated with four cycles of platinum-based doublet chemotherapy. Patients with an objective response or stable disease were then randomly assigned to treatment with erlotinib or placebo. EGFR mutation status was not determined prior to inclusion in the clinical trial.",
"   </p>",
"   <p>",
"    Subsequently, tumor samples were analyzed for an EGFR mutation in 437 of the randomized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/2\">",
"     2",
"    </a>",
"    ]. EGFR mutations were detected in 49 cases (11 percent) while 388 were wild type (89 percent). For patients with an EGFR mutation, progression-free survival was significantly increased in those receiving maintenance",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    compared with placebo (median 45 versus 13 weeks, HR for progression 0.10, 95% CI 0.04-0.25). Differences in overall survival were not statistically significant for patients with an EGFR mutation, but 67 percent of patients given a placebo subsequently received an EGFR TKI as second line therapy.",
"   </p>",
"   <p>",
"    The results in patients without an EGFR mutation in the SATURN trial are discussed separately. (See",
"    <a class=\"local\" href=\"#H1848339467\">",
"     'Erlotinib'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848338461\">",
"    <span class=\"h1\">",
"     PATIENTS WITHOUT A DRIVER MUTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized clinical trials have evaluated the role of maintenance therapy in patients with advanced NSCLC prior to routine testing for the presence of driver mutations in the tumor. In this setting, both single agent cytotoxic chemotherapy and EGFR TKIs significantly prolong progression-free survival and may improve overall survival.",
"   </p>",
"   <p>",
"    There are no randomized trials that directly compare maintenance using a single chemotherapy agent with an EGFR TKI. We prefer maintenance with a chemotherapy agent in patients known not to have an EGFR mutation, although an EGFR TKI is an alternative for patients not able or willing to be treated with maintenance chemotherapy. Furthermore, selected patients who desire a treatment break after their initial chemotherapy and do not appear to be at risk for rapid relapse can be watched with close clinical and radiographic monitoring, following an informed discussion with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Cytotoxic chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    all have significantly prolonged progression free survival when used as single agent maintenance therapy after initial chemotherapy for advanced NSCLC.",
"   </p>",
"   <p>",
"    There are no randomized clinical trials that compare these three agents as maintenance therapy. The most extensive data are from trials using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , which we prefer for patients with non-squamous carcinomas particularly if pemetrexed was used in the front line regimen. Either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    is preferred for patients with squamous cell carcinomas, and both are appropriate as alternatives to pemetrexed for patients with non-squamous NSCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848339075\">",
"    <span class=\"h3\">",
"     Pemetrexed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from two large trials indicated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    significantly prolongs both progression free survival and overall survival, when pemetrexed is used alone for maintenance therapy after the initial chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest phase III trial, 745 patients were treated with four cycles of a platinum-based doublet (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/4\">",
"       4",
"      </a>",
"      ]. Of these, 663 patients had an ongoing response or stable disease at the completion of chemotherapy and were then randomly assigned to receive either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      or placebo.",
"      <br/>",
"      <br/>",
"      Maintenance therapy with pemetrexed increased both median progression-free survival (4.3 versus 2.6 months, HR 0.50, 95% CI 0.42-0.61) and median overall survival compared with placebo (13.4 versus 10.6 months, HR 0.79, 95% CI 0.65-0.95). However, only 19 percent of those initially treated with placebo subsequently received pemetrexed. Patients treated with pemetrexed had a statistically significant longer time to worsening of pain and hemoptysis compared with placebo (HRs 0.76, 95% CI 0.59-0.99 and 0.58, 95% CI 0.34-0.97, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In preplanned subset analyses, patients with nonsquamous NSCLC had statistically significant improvements in both progression-free and overall survival with pemetrexed compared to placebo (4.5 versus 2.6 and 15.5 versus 10.3 months, respectively). In contrast, patients with squamous carcinoma",
"      <sup>",
"      </sup>",
"      showed no evidence of benefit in terms of either progression-free or overall survival (2.8 versus 2.6 and 9.9 versus 10.8 months, respectively). This differential activity of pemetrexed based upon histology is consistent with observations in trials where pemetrexed was used as part of the initial chemotherapy regimen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H12#H12\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Effect of histology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In the PARAMOUNT trial, 939 previously untreated patients were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      for non-squamous NSCLC [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. The 539 patients who had an objective response or stable disease after four cycles of treatment were randomly assigned to pemetrexed or placebo.",
"      <br/>",
"      <br/>",
"      Progression-free survival was significantly increased with pemetrexed compared with placebo (median 4.1 versus 2.8 months, HR 0.62, 95% CI 0.49-0.79) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/6\">",
"       6",
"      </a>",
"      ]. Overall survival, measured from randomization to maintenance therapy was significantly increased with pemetrexed compared with placebo (median 13.9 versus 11.0 months, one year survival rate 58 versus 45 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Trials in which the initial chemotherapy regimen included",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    and the potential combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    with bevacizumab for maintenance are discussed below. (See",
"    <a class=\"local\" href=\"#H1848341651\">",
"     'Role of bevacizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848339083\">",
"    <span class=\"h3\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    increases progression free survival and may improve overall survival in patients who have an objective response or stable disease after completion of four cycles of chemotherapy.",
"   </p>",
"   <p>",
"    In a phase III trial, 566 patients were initially treated with four cycles of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/8\">",
"     8",
"    </a>",
"    ]. The 309 patients without evidence of disease progression after completion of their chemotherapy were randomly assigned to immediate treatment with single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    for up to six cycles or to observation and treatment with docetaxel when disease progression occurred.",
"   </p>",
"   <p>",
"    Progression-free survival from randomization was significantly increased with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    compared with observation (median 5.7 versus 2.7 months), and there was no detriment in quality of life. Immediate treatment with docetaxel was associated with a trend toward prolonged survival, measured from randomization (median 12.3 versus 9.7 months with delayed chemotherapy, p = 0.09). Among those randomly assigned to delayed treatment, only 98 of 156 (63 percent) actually were treated with docetaxel. Patients who were treated with docetaxel as delayed therapy had a comparable outcome to those who received it early.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848339091\">",
"    <span class=\"h3\">",
"     Gemcitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     Gemcitabine",
"    </a>",
"    has been studied as maintenance therapy in one phase III trial, which demonstrated a statistically significant improvement in progression free survival and a trend toward improved overall survival.",
"   </p>",
"   <p>",
"    In a French multicenter trial, 834 patients with previously untreated, advanced NSCLC were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/9\">",
"     9",
"    </a>",
"    ]. The 464 patients with an objective response or stable disease after four cycles of chemotherapy were randomly assigned to observation, maintenance with gemcitabine, or maintenance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     Pemetrexed",
"    </a>",
"    was planned as second line therapy on all three arms for progression. The trial was designed to compare both gemcitabine and erlotinib with observation, but was not powered to compare gemcitabine with erlotinib.",
"    <br/>",
"    <br/>",
"    Progression-free survival was significantly prolonged in patients receiving gemcitabine maintenance regimen compared with observation (3.8 versus 1.9 months, HR 0.56). There was a statistically nonsignificant trend toward improved overall survival with gemcitabine maintenance compared to observation (median survival 12.1 versus 10.7 months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     EGFR TK inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single agent therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    significantly prolonged progression free survival when used as maintenance therapy after initial chemotherapy for advanced NSCLC in at least five randomized trials, in which patients were not selected based upon an analysis of EGFR mutation status. The impact of EGFR TKI maintenance therapy on overall survival is less clear from these trials.",
"   </p>",
"   <p>",
"    There are no clinical trials that compare",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    as maintenance therapy in patients with advanced NSCLC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848339467\">",
"    <span class=\"h3\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     Erlotinib",
"    </a>",
"    was evaluated as maintenance monotherapy in two large randomized trials, both of which demonstrated a statistically significant improvement in progression free survival. Erlotinib was also evaluated in the ATLAS trial, in which erlotinib plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was compared with bevacizumab alone. (See",
"    <a class=\"local\" href=\"#H1848341651\">",
"     'Role of bevacizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the SATURN trial, 1949 patients with previously untreated advanced NSCLC were treated with four cycles of platinum-based doublet chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/3\">",
"       3",
"      </a>",
"      ]. The 889 patients with an objective response or stable disease were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or placebo.",
"      <br/>",
"      <br/>",
"      Progression-free survival was significantly prolonged with erlotinib compared with placebo (median 12.3 versus 11.1 weeks). The improvement in progression-free survival was seen both in patients with adenocarcinoma and squamous carcinoma. For the entire study population, there was a statistically significant increase in overall survival (median 12.0 versus 11.0 months). Analysis of overall survival potentially was confounded by the subsequent use of EGFR tyrosine kinase inhibitors.",
"      <br/>",
"      <br/>",
"      The SATURN trial provides additional evidence that erlotinib has activity in patients with wild-type EGFR. Tumor samples were analyzed for EGFR mutation in 437 of the randomized patients [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/2\">",
"       2",
"      </a>",
"      ]. EGFR mutations were detected in 49 cases (11 percent) while 388 were wild type (89 percent). Patients with wild type EGFR had a significant increase in progression-free survival (HR 0.78, 95% CI 0.63-0.96). The results in patients with an EGFR mutation are discussed separately. (See",
"      <a class=\"local\" href=\"#H1848338860\">",
"       'Patients with a driver mutation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a French trial, patients with previously untreated, advanced NSCLC were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/9\">",
"       9",
"      </a>",
"      ]. The 464 patients with an objective response or stable disease after four cycles of chemotherapy were randomly assigned to observation, maintenance with gemcitabine, or maintenance with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      . Planned second line therapy for all three arms was",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      Progression-free survival was significantly prolonged with erlotinib maintenance compared to observation (2.9 versus 1.9 months, HR 0.69). There was a statistically nonsignificant trend toward improved overall survival with erlotinib versus observation (median 11.8 versus 10.7 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848339475\">",
"    <span class=\"h3\">",
"     Gefitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two clinical trials have used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    for maintenance therapy after initial treatment with a platinum-based doublet regimen. Both demonstrated a statistically significant improvement in progression free survival.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Japanese phase III trial (WJTOG0203), 604 patients were randomly assigned to three to six cycles of chemotherapy with a platinum-based doublet without maintenance therapy or to three cycles of chemotherapy followed by maintenance",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      (250",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/10\">",
"       10",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Progression free survival was significantly longer with gefitinib compared with observation (4.6 versus 4.3 months, HR 0.68). The difference in overall survival for the entire cohort was not statistically significant (13.7 versus 12.9 months, HR 0.86, 95% CI 0.72-1.03), but it was significant for those with adenocarcinoma (15.4 versus 14.3 months, HR 0.79, 95% CI 0.65-0.98). Interpretation of this study was made difficult by the fact that 50 percent of those given chemotherapy alone received gefitinib post-study, and 37 percent of both groups received second-line chemotherapy.",
"      <br/>",
"      <br/>",
"      Exploratory subset analyses showed no difference in survival between the two treatment arms among never-smokers, most of whom received gefitinib as second-line treatment. In smokers and in those with adenocarcinoma, there was an improvement in overall survival for the sequential strategy.",
"     </li>",
"     <li>",
"      In a Chinese trial, 296 patients were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      or placebo after completing four cycles of platinum-based doublet chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/11\">",
"       11",
"      </a>",
"      ]. Progression-free survival was significantly longer with gefitinib (median 4.8 versus 2.6 months). There difference in overall survival was not statistically significant (HR 0.84, 95% CI 0.62-1.14).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1848341651\">",
"    <span class=\"h2\">",
"     Role of bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     Bevacizumab",
"    </a>",
"    is frequently included with a platinum-based doublet in the initial chemotherapy regimen. In this setting, bevacizumab is usually continued as maintenance therapy after completion of the initial cycles of chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of maintenance chemotherapy or an EGFR TKI, either in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    or instead of bevacizumab, remains uncertain. Two trials evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    in this situation and one trial evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PointBreak trial failed to demonstrate a benefit from adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      as maintenance [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/12\">",
"       12",
"      </a>",
"      ]. Patients (n = 939) with advanced nonsquamous NSCLC were randomly assigned to pemetrexed,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      , plus bevacizumab or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , carboplatin, plus bevacizumab. Patients on both arms who were progression-free after four cycles were continued on bevacizumab. Those patients assigned to the pemetrexed regimen received pemetrexed in combination with bevacizumab, while those who had been on the paclitaxel regimen received maintenance bevacizumab alone.",
"      <br/>",
"      <br/>",
"      Preliminary results were presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. There was no difference in overall survival between the pemetrexed-based and paclitaxel-based regimens (median 12.6 versus 13.4 months, HR 1.00), nor were there statistically significant differences in the planned secondary endpoints (progression-free survival, objective response rate, and disease-control rate).",
"      <br/>",
"      <br/>",
"      Patients assigned to the pemetrexed plus bevacizumab regimen had significantly more grade 3 or 4 anemia, thrombocytopenia, and fatigue, while those assigned to the paclitaxel-based regimen experience significantly more grade 3 or 4 neutropenia, febrile neutropenia, and sensory neuropathy. Complete alopecia was significantly less common with the pemetrexed regimen (1.1 versus 21.4 percent).",
"     </li>",
"     <li>",
"      In contrast, the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      significantly increased progression free survival in the AVAPERL trial [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/13\">",
"       13",
"      </a>",
"      ]. All patients initially were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , pemetrexed, and bevacizumab; overall, 253 of 376 patients (67 percent) had an objective response or stable disease. Patients were randomly assigned to pemetrexed or observation, with bevacizumab continued in the absence of severe toxicity.",
"      <br/>",
"      <br/>",
"      Preliminary results were presented at a median follow-up of 11 months. Progression-free survival after the completion of initial chemotherapy was significantly prolonged with pemetrexed (median 7.4 versus 3.7 months following randomization).",
"     </li>",
"     <li>",
"      In the ATLAS trial, 1160 patients were treated with a platinum-based doublet combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9768/abstract/14\">",
"       14",
"      </a>",
"      ]. At the end of four cycles patients were continued on bevacizumab and randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or placebo.",
"      <br/>",
"      <br/>",
"      Preliminary results presented at the ASCO meeting in 2009 found that progression-free survival was significantly increased in patients receiving bevacizumab plus erlotinib compared to bevacizumab plus placebo (median 4.8 versus 3.8 months, HR 0.72, 95% CI 0.59-0.88). The trial was stopped early based upon achieving the primary end point. Additional follow-up is required to assess the impact on overall survival. No data are available on the mutation status of these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    None of these trials address the role of maintenance therapy with single agent chemotherapy alone versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    alone. The role of maintenance chemotherapy in patients whose initial regimen included bevacizumab is being investigated further in the ongoing ECOG 5508 trial (",
"    <a class=\"external\" href=\"file://www.clinicaltrials.gov/ct2/show/NCT01107626?term=NCT01107626&amp;rank=1\">",
"     NCT01107626",
"    </a>",
"    ), in which patients are initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , and bevacizumab and then randomly assigned to continuation maintenance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , bevacizumab, or the combination of these two agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with advanced non-small cell lung cancer (NSCLC) treated initially with combination chemotherapy, indefinite continuation of the initial chemotherapy combination may improve progression-free survival but it increases toxicity and does not have a clinically significant impact on overall survival. However, maintenance therapy with either a single agent chemotherapy or an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can improve progression free survival and may improve overall survival in those with a continuing response or stable disease after the initial four to six cycles of combination chemotherapy. (See",
"      <a class=\"local\" href=\"#H1848339707\">",
"       'Approach to treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Duration of therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with advanced non-small cell lung cancer (NSCLC) should have tumor assessed for the presence of a somatic driver mutation (eg, EGFR, ALK fusion oncogene). The choice of initial therapy (chemotherapy versus molecularly targeted agents) is guided by this information. This information is also useful in guiding subsequent therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"       \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients whose tumor has a driver mutation and who have an objective response or stable disease after four to six cycles of an initial combination chemotherapy regimen that did not include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , we suggest maintenance therapy with either single agent chemotherapy or a targeted agent rather than with no therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There are no data directly comparing continuation of chemotherapy with a switch to a tyrosine kinase inhibitor. Factors that should be discussed with the patient in defining a treatment plan include the quality of the initial response to chemotherapy and the potential side effects of maintenance therapy. (See",
"      <a class=\"local\" href=\"#H1848338860\">",
"       'Patients with a driver mutation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose tumor does not contain a driver mutation and who have an objective response or stable disease after four to six cycles of an initial combination chemotherapy regimen that did not include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , we suggest maintenance therapy rather than observation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Maintenance therapy has been associated with prolonged progression free survival in multiple trials, and may prolong overall survival. However, selected patients who desire a treatment break after their initial chemotherapy and do not appear to be at risk for rapid relapse can be watched with close clinical and radiographic monitoring, following an informed discussion with the patient. (See",
"      <a class=\"local\" href=\"#H1848339707\">",
"       'Approach to treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Maintenance therapy with single agent chemotherapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      ) or with an EGFR TKI has been shown to improve progression free survival. We suggest maintenance therapy with single agent chemotherapy rather than an EGFR TKI (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Maintenance therapy with an EGFR TKI is an alternative, particularly for patients who wish to avoid the toxicity associated with chemotherapy. (See",
"      <a class=\"local\" href=\"#H1848338461\">",
"       'Patients without a driver mutation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with non-squamous NSCLC who are treated with maintenance chemotherapy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      are appropriate alternatives. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with squamous cell NSCLC who are treated with maintenance chemotherapy, we suggest either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/27/36279?source=see_link\">",
"       pemetrexed",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients whose tumor is not known to contain a driver mutation and who have an objective response or stable disease after four to six cycles of an initial combination chemotherapy regimen that included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , we suggest continued maintenance therapy with bevacizumab without the addition of maintenance chemotherapy or an EGFR TKI (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1848341651\">",
"       'Role of bevacizumab'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=see_link&amp;anchor=H525779160#H525779160\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Chemotherapy plus bevacizumab'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/1\">",
"      Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009; 27:6251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/2\">",
"      Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:4113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/3\">",
"      Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010; 11:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/4\">",
"      Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/5\">",
"      Belani CP, Brodowicz T, Ciuleanu TE, et al. Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 2012; 13:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/6\">",
"      Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 2012; 13:247.",
"     </a>",
"    </li>",
"    <li>",
"     Paz-Ares L, et al. PARAMOUNT: Final overall survival (OS) results of the phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo (plb) plus BSC immediately following induction treatment with pem plus cisplatin (cis) for advanced nonsquamous (NS) non-small cell lung cancer (NSCLC) (abstract #7507). J Clin Oncol 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/8\">",
"      Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009; 27:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/9\">",
"      P&eacute;rol M, Chouaid C, P&eacute;rol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2012; 30:3516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/10\">",
"      Takeda K, Hida T, Sato T, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010; 28:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/11\">",
"      Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial. Lancet Oncol 2012; 13:466.",
"     </a>",
"    </li>",
"    <li>",
"     Patel J, Socinski MA, Garon EB, et al. A Randomized, Open-label, Phase 3, Superiority Study Of Pemetrexed (Pem)+Carboplatin (Cb)+Bevacizumab (B) Followed By Maintenance Pem+B Versus Paclitaxel (Pac)+Cb+B Followed By Maintenance B In Patients (pts) With Stage IIIB Or IV Non-squamous Non-small Cell Lung Cancer (NS-NSCLC) (abstract LBPL1). J Thorac Oncol 2012; 9:S336.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/13\">",
"      Barlesi F, de CASTRO J, Dvornichenko V, et al. Final efficacy outcomes for patients with advanced nonsquamous non-small cell lung cancer randomized to continuation maintenance with bevacizumab or bevacizumab + pemetrexed after first-line bevacizumab-cisplatin + pemetrexed (abstract #LBA8002). European Multidisciplinary Cancer Congress 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9768/abstract/14\">",
"      Miller V, O'Connor P, Soh C. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) (abstract #LBA8002). J Clin Oncol 2009.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4618 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-202.43.93.2-49404BB9CF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9768=[""].join("\n");
var outline_f9_34_9768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1848339707\">",
"      APPROACH TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1848338860\">",
"      PATIENTS WITH A DRIVER MUTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1848338461\">",
"      PATIENTS WITHOUT A DRIVER MUTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Cytotoxic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1848339075\">",
"      - Pemetrexed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1848339083\">",
"      - Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1848339091\">",
"      - Gemcitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EGFR TK inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1848339467\">",
"      - Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1848339475\">",
"      - Gefitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1848341651\">",
"      Role of bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4618|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=related_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_34_9769="Complex atyp hyperplas endometr";
var content_f9_34_9769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atypical endometrial hyperplasia (complex)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The irregularly shaped glands in this case are very closely packed bu are still separated by residual endometrial stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Silverberg SG, Kurman RJ. Tumors of the Uterine Corpus and Gestational Trophoblastic Disease. AFIP Atlas of Tumor Pathology, version 2.0, American Registry of Pathology, Washington DC 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9769=[""].join("\n");
var outline_f9_34_9769=null;
var title_f9_34_9770="Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children";
var content_f9_34_9770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Ibrahim A Janahi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Khoulood Fakhoury, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/34/9770/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/34/9770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple parapneumonic effusion is defined as pleural effusion associated with lung infection (ie, pneumonia). These effusions result from the spread of inflammation and infection to the pleura. Much less commonly, infections in other adjacent areas (eg, retropharyngeal, vertebral, abdominal, and retroperitoneal spaces) may spread to the pleura resulting in the development of effusion.",
"   </p>",
"   <p>",
"    Early in the course of parapneumonic effusion, the pleura becomes inflamed; subsequent leakage of proteins, fluid, and leukocytes into the pleural space forms the effusion. At the time of formation, the pleural effusion is usually sterile with a low leukocyte count. With time, bacteria invade the fluid, resulting in empyema, which is defined as the presence of grossly purulent fluid in the pleural cavity. The development of pleural empyema is determined by a balance between host resistance, bacterial virulence, and timing of presentation for medical treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, etiology, pathophysiology, clinical presentation, and evaluation of parapneumonic effusion and empyema in children will be reviewed here. The management of parapneumonic effusion and empyema in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"     \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation and management of parapneumonic effusion in adults also are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=see_link\">",
"     \"Imaging of pleural effusions in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 1962 and 1980, empyema was reported to occur in approximately 0.6 percent of children with bacterial pneumonia, despite early diagnosis and treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the number of children with parapneumonic effusions appears to be increasing in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] and the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Prospective studies of community-acquired pneumonia in Europe and the United states reported parapneumonic effusion in 2 to 12 percent of hospitalized cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, the number of children admitted to Texas Children's Hospital with parapneumonic effusions increased steadily during sequential three-year periods between 1992 and 2000 (45, 58, and 141 during 1992 to 1994, 1995 to 1997, and 1998 to 2000, respectively). The increased incidence of parapneumonic effusions occurred coincident with a rise in antibiotic resistant organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/10\">",
"     10",
"    </a>",
"    ], and despite reductions in pneumococcal pneumonia achieved by use of the pneumococcal conjugate vaccine, perhaps because empyema is frequently caused by pneumococcal serotypes not included in the 7-valent conjugate vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/5,11,12\">",
"     5,11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Bacterial infections'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Empyemas occur twice as often in the spring and winter than in the summer and fall [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3,13\">",
"     3,13",
"    </a>",
"    ]. In studies from the 1980s, boys were affected more often than girls [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"     13",
"    </a>",
"    ], but in subsequent studies, boys and girls are equally affected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/4\">",
"     4",
"    </a>",
"    ]. The mortality rate is highest in children younger than 2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain underlying diseases may increase the risk of empyema in children. In one review of 61 children with parapneumonic empyema, 11 percent had an underlying illness or condition [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/15\">",
"     15",
"    </a>",
"    ]. Underlying problems may include: immunodeficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3,13,15,16\">",
"     3,13,15,16",
"    </a>",
"    ], influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/17\">",
"     17",
"    </a>",
"    ], malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/15\">",
"     15",
"    </a>",
"    ], Down syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3,13\">",
"     3,13",
"    </a>",
"    ], congenital thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/15\">",
"     15",
"    </a>",
"    ], cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3,13,15\">",
"     3,13,15",
"    </a>",
"    ], post-surgical [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/15,18,19\">",
"     15,18,19",
"    </a>",
"    ], tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/16\">",
"     16",
"    </a>",
"    ], congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"     13",
"    </a>",
"    ], prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"     13",
"    </a>",
"    ], history of esophageal stricture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13,15\">",
"     13,15",
"    </a>",
"    ], and cystic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empyema in children occurs primarily in association with an underlying pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13,20\">",
"     13,20",
"    </a>",
"    ]. The predominant causative organisms have changed over time, with the advent of antibiotic therapy, the development of antibiotic resistance, and the development and widespread use of polysaccharide and conjugate vaccines for Haemophilus influenzae type b and Streptococcus pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link\">",
"     \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H10#H10\">",
"     \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Pneumonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapneumonic effusions are mostly associated with bacterial pneumonia. Information regarding the predominant bacteria must be interpreted with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ], since the range of reported rates of identification of an infectious organism varies broadly with differences in definitions, inclusion and exclusion criteria, rates of pleural fluid sampling, culture and other microbiologic identification techniques, and pretreatment with antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/2,3,13,21,22\">",
"     2,3,13,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Before 1945, empyema in children was caused primarily by pneumococcal and streptococcal infections [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Following the introduction of sulfonamides and penicillin in the late 1940's, Staphylococcus aureus became the predominant cause of childhood empyema, and remained the leading etiology until the 1970s [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the 1980s, H. influenzae type b became the predominant etiologic organism for empyema in children, although S. pneumoniae and S. aureus remained common [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"       13",
"      </a>",
"      ]. Since the 1990s, H. influenzae type b has almost completely disappeared as a major pathogen in children, largely because of widespread immunization of infants [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During the 1980s, an increase in the incidence of the anaerobic bacteria such as Bacteroides and Fusobacterium species was also noted, particularly in debilitated or neurologically impaired children [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Streptococcus pneumoniae remains the most common pathogen causing parapneumonic effusions. During the 1980s and 1990s, there was a resurgence of penicillin and cephalosporin resistant S. pneumoniae; some of these virulent S. pneumoniae are now causing an increasing number of cases of necrotizing pneumonia and empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3,20,25-28\">",
"       3,20,25-28",
"      </a>",
"      ]. During 1999 and 2000, 98 children were admitted to Texas Children's Hospital with complicated parapneumonic effusions; 45 percent",
"      <span class=\"nowrap\">",
"       (44/98)",
"      </span>",
"      had positive cultures [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/29\">",
"       29",
"      </a>",
"      ]. Among the 25 patients who grew S. pneumoniae, 19 (76 percent) were penicillin nonsusceptible.",
"     </li>",
"     <li>",
"      Penicillin susceptible strains of S. pneumoniae also cause a substantial number of cases of empyema in some communities. Using molecular diagnostic techniques, S. pneumoniae serotype 1, a highly invasive serotype that is typically penicillin susceptible, was detected in almost half of the cases of empyema in one community [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/30\">",
"       30",
"      </a>",
"      ]. A high prevalence of serotypes 1, 3, 7F, or 19A was shown in case series from other centers in the United States [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/11,28,31,32\">",
"       11,28,31,32",
"      </a>",
"      ]. Similarly, in a series from Australia, about half of the empyemas were caused by S. pneumoniae, and almost all of these were caused by serotypes 1, 3, or 19A [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/33\">",
"       33",
"      </a>",
"      ]. In many of these cases the organism was not detectable by culture, probably due to pretreatment with antibiotics, pointing to the utility of molecular methods for microbial detection, such as polymerase change reaction (PCR). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Microbial analysis'",
"      </a>",
"      below.) &nbsp;",
"      <br/>",
"      <br/>",
"      Of note, serotypes 1, 3 17F and 19A are not included in the 7-valent pneumococcal conjugate vaccine that was used for the routine childhood immunization series until it was replaced by the 13-valent pneumococcal conjugate vaccine in 2010, which does include these serotypes. These serotypes are also included in the 23-valent polysaccharide vaccine that is recommended for patients at high risk of invasive disease (",
"      <a class=\"graphic graphic_table graphicRef77274 \" href=\"UTD.htm?14/59/15293\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=see_link&amp;anchor=H3#H3\">",
"       \"Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children\", section on 'Vaccine'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=see_link&amp;anchor=H3#H3\">",
"       \"Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children\", section on 'Conjugate vaccines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Community-associated methicillin-resistant Staphylococcus aureus is an increasingly common cause of both parapneumonic effusion and empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/10,29,34,35\">",
"       10,29,34,35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=see_link&amp;anchor=H19#H19\">",
"       \"Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children\", section on 'Clinical spectrum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some other less common bacteria are now being identified as a cause of some of the most notorious empyemas; these include viridans streptococcus [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/36\">",
"       36",
"      </a>",
"      ], group A Streptococcus (S. pyogenes), and Actinomyces species [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/24\">",
"       24",
"      </a>",
"      ]. Group A beta-hemolytic streptococcal infection, associated with empyema and toxic shock syndrome, has been reported as a complication of varicella, immune deficiency, and rarely in otherwise healthy children [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/37,38\">",
"       37,38",
"      </a>",
"      ] including neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Parapneumonic effusions have also been reported in up to 10 percent of viral and 20 percent of Mycoplasma pneumonia. However, these effusions are typically small and rarely require intervention in the absence of other underlying diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/9,40,41\">",
"     9,40,41",
"    </a>",
"    ] such as sickle cell disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Pneumonia'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pleural space is a potential anatomic space with a small amount of contained fluid. The boundaries of that space are the parietal pleura and the visceral pleura. Normally, fluid is filtered by the parietal pleura and is absorbed by the visceral pleura in a mechanism governed by Starling's equation, where both blood and pleural fluid are in a pressure balance (both hydrostatic and oncotic) so that no extra fluid accumulates in the pleural space. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9735?source=see_link\">",
"     \"Mechanisms of pleural liquid turnover in the normal state\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fluid accumulates in the pleural space when there is imbalance of hydrostatic and oncotic pressure between the blood and pleural fluid. Small amounts of protein that ooze to the pleural space are readily removed by the lymphatic system. It is only when extra amounts of protein leak into the pleural space (as occurs in pneumonia secondary to increased capillary permeability) that the lymphatic system fails to cope with the removal task and exudative pleural effusion ensues. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=see_link\">",
"     \"Mechanisms of pleural liquid accumulation in disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Stages",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parapneumonic effusion progresses in three loosely defined stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exudative. The first stage is known as the exudative stage. In this stage, the exudate is a simple, uncomplicated parapneumonic effusion that is characterized by normal glucose concentration, normal pH, and a low cellular count. In the exudative stage, the pleural fluid usually layers out on lateral decubitus chest radiographs (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51660 \" href=\"UTD.htm?9/48/9985\">",
"       image 1",
"      </a>",
"      ). This stage may last only 24 to 72 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fibrinopurulent. The second stage is known as the fibrinopurulent stage. In this stage, large numbers of polymorphonuclear cells accumulate in the pleural fluid; bacterial invasion and fibrin deposition on the pleural surfaces lead to thickening of the exudate and the formation of loculations, making drainage difficult [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. During this stage, the pleural fluid pH and glucose concentration decrease and lactate dehydrogenase (LDH) concentration increases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/43,44\">",
"       43,44",
"      </a>",
"      ]. Pleural effusions in the fibrinopurulent stage are sometimes called complicated pleural effusions. Loculated pleural effusions usually do not layer out on decubitus radiographs. This stage lasts 7 to 10 days [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Organizational. The third stage is known as the organizational stage. In this stage, fibroblasts grow on both parietal and visceral pleural surfaces, forming an inelastic membrane \"pleural peel\" that restricts lung reexpansion, impairs lung function, and creates a persistent pleural space with ongoing potential for infection [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"       21",
"      </a>",
"      ]. At this stage, thoracentesis may yield a \"dry tap\" [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"       13",
"      </a>",
"      ]. This stage typically occurs two to four weeks after initial development of the empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications associated with parapneumonic effusions and empyema are infrequent in children. They include bronchopleural fistula, lung abscess, and empyema necessitatis (perforation through the chest wall) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of the child with parapneumonic effusion or empyema depends to some extent upon when the child presents for medical attention. Some children present with symptoms related to empyema whereas others have been seen earlier in the course and appropriately treated for pneumonia, but fail to respond. Thus, any child who remains febrile or unwell 48 hours after initiation of antibiotic therapy for pneumonia should be reevaluated for potential complications with repeat examination and chest radiograph [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21,45\">",
"     21,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=see_link&amp;anchor=H2294532#H2294532\">",
"     \"Clinical features and diagnosis of community-acquired pneumonia in children\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptoms in children with empyema are persistent fever, malaise, decreased appetite, cough, chest pain, and dyspnea [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3,4,14,21,42\">",
"     3,4,14,21,42",
"    </a>",
"    ]. Children with empyema may lie on the affected side to splint the involved hemithorax and provide temporary analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ]. Weight loss can occur if the disease persists for longer than one to two weeks.",
"   </p>",
"   <p>",
"    On physical examination, children with empyema may appear ill, but only occasionally are toxic appearing. They rarely present in septic shock with hypotension and severe respiratory distress. Most children with parapneumonic effusions are tachypneic, but breaths may be shallow to minimize pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/14\">",
"     14",
"    </a>",
"    ]. Fever and cough are present in approximately 90 percent of patients with empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/3,46\">",
"     3,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chest examination may reveal a small degree of \"new' scoliosis, related to the child's splinting toward the affected side [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition there may be dullness to percussion, decreased air exchange, and possibly a pleural rub, on the side of the fluid collection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/14,21,42\">",
"     14,21,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mediastinal shift and tension hydrothorax have been reported in patients in whom large volumes of pleural fluid (ie, &gt;1000 mL) cause compression of the lung [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]. Hypoalbuminemia is common, particularly in children with large effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/50\">",
"     50",
"    </a>",
"    ]. In many patients this is probably caused by shifting of albumin from the serum to the pleural space. Other causes of hypoalbuminemia such as urinary or fecal protein loss and",
"    <span class=\"nowrap\">",
"     malnutrition/catabolic",
"    </span>",
"    state should be considered.",
"   </p>",
"   <p>",
"    Secondary thrombocytosis (ie, platelet count of",
"    <span class=\"nowrap\">",
"     &gt;500,000/microL)",
"    </span>",
"    is common (present in 93 percent of children in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/51\">",
"     51",
"    </a>",
"    ]), but is benign. Thrombocytosis peaks at two to three weeks, and usually returns to normal after three weeks of illness. Antiplatelet therapy is not necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History and examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the findings that support a diagnosis of parapneumonic effusion described above, it is important to assess the severity of illness and to look for signs of underlying conditions that predispose to the development of parapneumonic effusion. Pulse oximetry is useful in determining the presence and severity of hypoxia. Oxygen saturation &lt;92 percent indicates severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21,45\">",
"     21,45",
"    </a>",
"    ]. The child's state of hydration should be assessed so that fluid therapy can be initiated, if necessary.",
"   </p>",
"   <p>",
"    The child's history, general appearance, height, weight, dermatologic and neurologic examinations may provide clues to underlying disorders that predispose to the development of parapneumonic effusion:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of recurrent serious bacterial infections, failure to thrive,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chronic diarrhea or diaper rash is suggestive of primary immunodeficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"       \"Approach to the child with recurrent infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with Down syndrome have a characteristic appearance. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poor weight gain or short stature may indicate immune deficiency, cystic fibrosis, or other chronic disease. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Abnormalities of motor and postural function are suggestive of cerebral palsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=see_link\">",
"       \"Clinical features of cerebral palsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Features of the history that suggest malignant, rather than parapneumonic, effusion include the absence of acute fever or pneumonia, and evidence of an underlying mediastinal mass or lymphadenopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"       21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"       \"Clinical assessment of the child with suspected cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postero-anterior (PA) or antero-posterior (AP) and lateral decubitus radiographs can help in making the diagnosis of pleural effusion and in determining the need for thoracentesis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest-tube placement. These radiographs also can facilitate differentiation between free fluid and loculated effusion. In addition, chest radiographs may reveal other findings that help in predicting the underlying cause of the effusion (eg, cardiomegaly, hilar lymphadenopathy, bone lesions, etc) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/52\">",
"     52",
"    </a>",
"    ]. However, radiographs alone cannot differentiate empyema from parapneumonic effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21,53\">",
"     21,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"     \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic signs of pleural effusion include obliteration of the costophrenic angle, the \"meniscus sign\" (a rim of fluid ascending the lateral chest wall), and scoliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ], particularly in patients with illness of more than one week's duration [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/15\">",
"     15",
"    </a>",
"    ]. Air-fluid levels in the pleural space suggest the presence of gas forming organisms, pneumothorax, perforated viscus, or bronchopleural fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decubitus or cross-table view permits free fluid to layer out on the dependent chest wall and can help to distinguish the meniscus from pleural thickening [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/14\">",
"     14",
"    </a>",
"    ]. In older children and adults, a decubitus layer of &gt;1 cm is considered sufficient volume to attempt to extract by thoracentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is frequently obtained in the evaluation of patients with pleural effusion. It is useful in confirming the presence of fluid in the pleural space (particularly when there is \"white out\" on plain radiograph) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/52\">",
"     52",
"    </a>",
"    ]. Ultrasonography is also useful in the detection of early loculations and septations, the determination of the nature of the effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/55\">",
"     55",
"    </a>",
"    ], quantification of the effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/56\">",
"     56",
"    </a>",
"    ], and the localization of optimal sites for thoracentesis or chest tube insertion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. An ultrasonographic scoring system has been proposed to aid in determining the best approach to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/60\">",
"     60",
"    </a>",
"    ]. Other advantages of ultrasonography compared to computed tomography include its ready availability, lack of radiation exposure, and lack of need for sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chest CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest computed tomography (CT) also can be helpful in determining the presence of pleural fluid. However, studies have suggested that CT findings lack the accuracy to characterize the nature of fluid and the presence of empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/61\">",
"     61",
"    </a>",
"    ] and do not seem to affect management decisions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Computed tomography should not be performed routinely in the evaluation of children with parapneumonic effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ]. However, computed tomography may play a role in the evaluation of complicated cases, including failure to aspirate pleural fluid, failure of medical management, and immunocompromised children, in whom CT may reveal other clinical problems [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, CT may be required by surgeons before surgery (thoracotomy or thoracoscopy) to delineate anatomy and exclude intrapulmonary abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"     \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9786692\">",
"    <span class=\"h2\">",
"     Blood and sputum cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood cultures should be performed in all children with parapneumonic effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ]. Blood cultures are positive in 10 to 22 percent of children with complicated parapneumonic effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/4,26\">",
"     4,26",
"    </a>",
"    ] and are particularly helpful if pleural fluid culture is negative.",
"   </p>",
"   <p>",
"    Sputum cultures (if patient is able to expectorate) or tracheal aspirates should be sent for bacterial culture if they are available; organisms cultured from the nasopharynx or throat are not necessarily present in the lower airways [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ]. The yield of cultures decreases sharply after systemic or oral antibiotics are given. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=see_link&amp;anchor=H9#H9\">",
"     \"Sputum cultures for the evaluation of bacterial pneumonia\", section on 'Interpretation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Pleural fluid analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid should be sent for analysis if thoracocentesis or drainage of pleural fluid is indicated or if a non infectious etiology is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/9,21\">",
"     9,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link&amp;anchor=H13#H13\">",
"     \"Management and prognosis of parapneumonic effusion and empyema in children\", section on 'Thoracentesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic evaluation of pleural fluid, including empyema, is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .) Information that can be obtained from pleural fluid analysis that may relate to the management of children with empyema is presented briefly below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Microbial analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural fluid must be sent for microbiologic analysis including Gram stain and bacterial culture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ]; these were reported to be positive in up to 49 percent of cases, with most studies reporting positive culture in less than 25 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/9\">",
"     9",
"    </a>",
"    ]. However, pleural fluid cultures are often sterile because of prior administration of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Additional techniques may be used to increase the yield of microbiologic diagnosis in children who have received antibiotics. These include: direct and enrichment culture for aerobic and anaerobic organisms, pneumococcal antigen detection (latex agglutination) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/64,65\">",
"     64,65",
"    </a>",
"    ] and specific or broad range polymerase chain reaction (PCR) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/31,65-68\">",
"     31,65-68",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumococcal antigen detection &ndash; Pneumococcal antigen detection in pleural fluid samples by latex agglutination is useful in the rapid diagnosis of pneumococcal empyema, particularly in patients who have received antibiotics before pleural fluid aspiration. The value of this assay was evaluated in a study of pleural fluid samples from 78 children with empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/65\">",
"       65",
"      </a>",
"      ]. Pleural fluid specimens were sent for standard culture, pneumococcal antigen detection, broad range PCR (16S rDNA PCR), and specific PCR (pneumolysin PCR). A microbiologic diagnosis was confirmed by culture or broad range PCR in 60 cases (77 percent). Among the 40 cases of pneumococcal empyema, 23 were diagnosed with PCR and culture and 17 with PCR alone (all 17 had received antibiotics before pleural fluid aspiration). Latex agglutination testing identified pneumococcal antigen in the pleural fluid of 90 percent of cases of pneumococcal empyema, and was negative in 95 percent of non-pneumococcal empyema (ie, sensitivity and specificity of 90 and 95 percent, respectively). &nbsp;",
"     </li>",
"     <li>",
"      Polymerase Chain Reaction (PCR) &ndash; Detection of specific pathogens in pleural fluid through PCR also can be used if the organism is not readily identified by culture or pneumococcal antigen detection [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/9\">",
"       9",
"      </a>",
"      ]. If a broad-range PCR is not available, specific testing should be done for S. pneumoniae (pneumococcus) and S. pyogenes. However, the degree to which PCR improves yield as compared to conventional culture techniques is not clear, because studies report highly varied sensitivities [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/66-70\">",
"       66-70",
"      </a>",
"      ]. Moreover, PCR results have limited value in determining antibiotic treatment choices because they do not provide information about antibiotic resistance in the identified strain of bacteria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=see_link&amp;anchor=H9960403#H9960403\">",
"       \"Pneumococcal pneumonia in children\", section on 'Polymerase chain reaction'",
"      </a>",
"      .) &nbsp; &nbsp; &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Biochemical studies &mdash; Pleural fluid pH, glucose, and LDH are helpful in confirming the diagnosis of empyema if the diagnosis is in doubt or in the setting of an underlying condition such as collagen-vascular disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=see_link&amp;anchor=H4#H4\">",
"       \"Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\", section on 'Extraarticular manifestations'",
"      </a>",
"      ). These studies have a questionable role in making management decisions and there is geographic variation in their use. More aggressive intervention (ie, chest drain placement, VATS) is often undertaken if pH is &lt;7.0, glucose is &lt;40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.22",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      or LDH is &gt;1000 IU (16.67",
"      <span class=\"nowrap\">",
"       kat/L).",
"      </span>",
"      However, in most instances the decision to drain a parapneumonic effusion is made on clinical grounds (eg, the presence of pus, clinical status of the patient) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/52,71\">",
"       52,71",
"      </a>",
"      ], and routine aspiration of pleural fluid is not usually performed solely for the purpose of biochemical analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21,52\">",
"       21,52",
"      </a>",
"      ]. The Pediatric Infectious Disease",
"      <span class=\"nowrap\">",
"       Society/Infectious",
"      </span>",
"      Diseases Society of America guideline states that analysis of pleural fluid parameters, such as pH and levels of glucose, protein, and lactate dehydrogenase, rarely change management of a patient with community-acquired pneumonia and are not recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/9\">",
"       9",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link\">",
"       \"Management and prognosis of parapneumonic effusion and empyema in children\"",
"      </a>",
"      .) &nbsp; &nbsp; &nbsp;",
"      <br/>",
"      <br/>",
"      It is important to keep pleural fluid specimens tightly capped and on ice to prevent spurious changes in pH or glucose levels. Testing should be performed immediately or fluid should be stored at 0&ordm;C for no more than two hours; pH is lowered if fluid is stored at room temperature and raised upon exposure to air [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cell count &mdash; Pleural fluid should be sent for differential cell count [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"       21",
"      </a>",
"      ]. This is helpful in differentiating bacterial from mycobacterial, fungal, or malignant etiologies. Nucleated white blood cell counts above 50,000",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      are typical of complicated parapneumonic effusions, including empyema, but cell counts may be between 10,000 and 50,000 early in the course of the illness. Chronic exudates (eg, from tuberculous pleurisy and malignancy), tend to have low nucleated cell counts. The differential cell count can be helpful in determining an etiology; mononuclear predominance suggests malignancy or tuberculosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/73-76\">",
"       73-76",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link&amp;anchor=H19#H19\">",
"       \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\", section on 'Nucleated cells'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=see_link\">",
"       \"Tuberculous pleural effusions in HIV-negative patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cytology &mdash; Pleural fluid should be sent for cytology if there is any suspicion that the effusion is not secondary to infection (eg, absence of pneumonia or fever, or presence of mediastinal mass or lymphadenopathy) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"       21",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Bronchoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flexible bronchoscopy is not indicated and it is not routinely recommended for children with parapneumonic effusion unless foreign body aspiration is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=see_link\">",
"     \"Airway foreign bodies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional tests may be indicated in the diagnosis or assessment of severity of parapneumonic effusions in children. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tuberculin skin testing (TST) and sputum (or gastric aspirates) for acid fast bacilli should be performed if risk factors for tuberculosis are present; TST may be falsely negative (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=see_link\">",
"       \"Tuberculous pleural effusions in HIV-negative patients\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Measurement of various serum titers (eg, mycoplasma, antistreptolysin O, respiratory viruses) may indicate the causative organism, but the need for acute and convalescent samples limits the utility of these tests in early management.",
"     </li>",
"     <li>",
"      Complete blood count with differential may indicate evidence of infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      anemia (present at some point in approximately 20 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"       13",
"      </a>",
"      ]). The white blood cell count may be helpful in monitoring progress, but does not help in distinguishing complicated from uncomplicated effusions [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/43,77\">",
"       43,77",
"      </a>",
"      ]. Secondary thrombocytosis (ie, platelet count of",
"      <span class=\"nowrap\">",
"       &gt;500,000/microL)",
"      </span>",
"      and hypoalbuminemia are common. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Similarly, C-reactive protein may be useful in monitoring progress [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Serum electrolytes (to detect inappropriate secretion of antidiuretic hormone [ADH]) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/78,79\">",
"       78,79",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link&amp;anchor=H13#H13\">",
"       \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\", section on 'Pulmonary disease'",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Serum LDH is helpful to compare with that in pleural fluid (a pleural fluid",
"      <span class=\"nowrap\">",
"       LDH/serum",
"      </span>",
"      LDH ratio greater than 0.6 is indicative of empyema [",
"      <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/42\">",
"       42",
"      </a>",
"      ]).",
"     </li>",
"     <li>",
"      Blood gases and pH may show evidence of respiratory alkalosis in the tachypneic child, or metabolic acidosis in the septic child, but usually shows a mixed picture. These tests are not routinely indicated unless the child appears to have sepsis, requires high concentrations of supplemental oxygen, is in severe respiratory distress, or suspected to be in respiratory failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of the above discussion regarding the clinical presentation and evaluation of children with parapneumonic effusion and is consistent with the guidelines published by the Pediatric Infectious Diseases",
"    <span class=\"nowrap\">",
"     Society/Infectious",
"    </span>",
"    Diseases Society of America and the British Thoracic Society [",
"    <a class=\"abstract\" href=\"UTD.htm?9/34/9770/abstract/9,21\">",
"     9,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of parapneumonic effusions appears to be increasing in the United States and the United Kingdom. Empyema in children occurs primarily in association with underlying pneumonia. The causative organisms have changed over time. S. pneumoniae is the predominant organism, and antibiotic resistant strains are particularly important. In addition, community-acquired S. aureus is becoming more common. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presenting symptoms in children with empyema are fever, cough, malaise, anorexia, chest pain, and dyspnea. Failure to improve after 48 hours of appropriate therapy for pneumonia is another important presenting scenario. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with the above clinical findings should be evaluated with chest radiograph. Ultrasound may be needed to determine if the effusion is loculated. Cultures of blood and sputum (if the patient is able to expectorate) should be obtained. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Radiologic evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9786692\">",
"       'Blood and sputum cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If thoracocentesis or drainage of pleural fluid is indicated or if a non-infectious etiology is suspected, pleural fluid should be sent for analysis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=see_link&amp;anchor=H13#H13\">",
"       \"Management and prognosis of parapneumonic effusion and empyema in children\", section on 'Thoracentesis'",
"      </a>",
"      ). The pleural fluid should be sent for the following studies: &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Gram stain and culture (aerobic and anaerobic). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Microbial analysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cell count and differential. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      pH, glucose, and LDH may not affect clinical management decision; therefore, they are not routinely indicated unless the diagnosis is questionable. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional pleural fluid studies that may improve the yield of identifying the etiology, and are particularly useful if the child received antibiotics before pleural fluid was obtained, include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pneumococcal antigen detection (latex agglutination studies). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Microbial analysis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Specific or broad range PCR studies",
"     </li>",
"     <li>",
"      Cytology if malignancy is suspected (eg, because of lymphocytic predominance on cell count, mediastinal mass or lymphadenopathy) (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Other studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other tests that may be helpful in identifying the causative organism, assessment of severity, presence of complications, and monitoring progress include: (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other tests'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tuberculin skin testing and sputum (or gastric aspirates) for acid fast bacilli in patients with risk factors for tuberculosis",
"     </li>",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      C-reactive protein may be useful in monitoring progress",
"     </li>",
"     <li>",
"      Serum electrolytes (to detect inappropriate ADH syndrome)",
"     </li>",
"     <li>",
"      Serum LDH, used to calculate the pleural to serum LDH ratio &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with parapneumonic effusion who have a history of recurrent bacterial infections, poor growth, or had S. aureus or P. aeruginosa as the infecting organism, should be evaluated for cystic fibrosis and immunodeficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link\">",
"       \"Cystic fibrosis: Clinical manifestations and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link&amp;anchor=H23#H23\">",
"       \"Approach to the child with recurrent infections\", section on 'Laboratory evaluation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/1\">",
"      Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332:1280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/2\">",
"      Chonmaitree T, Powell KR. Parapneumonic pleural effusion and empyema in children. Review of a 19-year experience, 1962-1980. Clin Pediatr (Phila) 1983; 22:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/3\">",
"      Hardie W, Bokulic R, Garcia VF, et al. Pneumococcal pleural empyemas in children. Clin Infect Dis 1996; 22:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/4\">",
"      Byington CL, Spencer LY, Johnson TA, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis 2002; 34:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/5\">",
"      Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics 2010; 125:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/6\">",
"      Rees JH, Spencer DA, Parikh D, Weller P. Increase in incidence of childhood empyema in West Midlands, UK. Lancet 1997; 349:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/7\">",
"      Playfor SD, Smyth AR, Stewart RJ. Increase in incidence of childhood empyema. Thorax 1997; 52:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/8\">",
"      Roxburgh CS, Youngson GG, Townend JA, Turner SW. Trends in pneumonia and empyema in Scottish children in the past 25 years. Arch Dis Child 2008; 93:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/9\">",
"      Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/10\">",
"      Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural empyemas in children: epidemiology and management. Pediatrics 2004; 113:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/11\">",
"      Byington CL, Hulten KG, Ampofo K, et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol 2010; 48:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/12\">",
"      Grijalva CG, Nuorti JP, Zhu Y, Griffin MR. Increasing incidence of empyema complicating childhood community-acquired pneumonia in the United States. Clin Infect Dis 2010; 50:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/13\">",
"      Freij BJ, Kusmiesz H, Nelson JD, McCracken GH Jr. Parapneumonic effusions and empyema in hospitalized children: a retrospective review of 227 cases. Pediatr Infect Dis 1984; 3:578.",
"     </a>",
"    </li>",
"    <li>",
"     Wheeler JG, Jacobs RF. Pleural effusions and empyema. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.325.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/15\">",
"      Hoff SJ, Neblett WW, Edwards KM, et al. Parapneumonic empyema in children: decortication hastens recovery in patients with severe pleural infections. Pediatr Infect Dis J 1991; 10:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/16\">",
"      Lewis KT, Bukstein DA. Parapneumonic empyema in children: diagnosis and management. Am Fam Physician 1992; 46:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/17\">",
"      Ampofo K, Herbener A, Blaschke AJ, et al. Association of 2009 pandemic influenza A (H1N1) infection and increased hospitalization with parapneumonic empyema in children in Utah. Pediatr Infect Dis J 2010; 29:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/18\">",
"      Golladay ES, Wagner CW. Management of empyema in children. Am J Surg 1989; 158:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/19\">",
"      Brook I. Microbiology of empyema in children and adolescents. Pediatrics 1990; 85:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/20\">",
"      Bryant RE, Salmon CJ. Pleural empyema. Clin Infect Dis 1996; 22:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/21\">",
"      Balfour-Lynn IM, Abrahamson E, Cohen G, et al. BTS guidelines for the management of pleural infection in children. Thorax 2005; 60 Suppl 1:i1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/22\">",
"      Alkrinawi S, Chernick V. Pleural infection in children. Semin Respir Infect 1996; 11:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/23\">",
"      B&eacute;champs GJ, Lynn HB, Wenzl JE. Empyema in children: review of mayo clinic experience. Mayo Clin Proc 1970; 45:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/24\">",
"      Givan DC, Eigen H. Common pleural effusions in children. Clin Chest Med 1998; 19:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/25\">",
"      Kerem E, Bar Ziv Y, Rudenski B, et al. Bacteremic necrotizing pneumococcal pneumonia in children. Am J Respir Crit Care Med 1994; 149:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/26\">",
"      Buckingham SC, King MD, Miller ML. Incidence and etiologies of complicated parapneumonic effusions in children, 1996 to 2001. Pediatr Infect Dis J 2003; 22:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/27\">",
"      Hardie WD, Roberts NE, Reising SF, Christie CD. Complicated parapneumonic effusions in children caused by penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics 1998; 101:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/28\">",
"      Tan TQ, Mason EO Jr, Wald ER, et al. Clinical characteristics of children with complicated pneumonia caused by Streptococcus pneumoniae. Pediatrics 2002; 110:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/29\">",
"      Quintero DR, Fan LL. Approach to pleural effusions and empyemas. Paediatr Respir Rev 2004; 5 Suppl A:S151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/30\">",
"      Obando I, Mu&ntilde;oz-Almagro C, Arroyo LA, et al. Pediatric parapneumonic empyema, Spain. Emerg Infect Dis 2008; 14:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/31\">",
"      Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J 2011; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/32\">",
"      Yu J, Salamon D, Marcon M, Nahm MH. Pneumococcal serotypes causing pneumonia with pleural effusion in pediatric patients. J Clin Microbiol 2011; 49:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/33\">",
"      Strachan RE, Cornelius A, Gilbert GL, et al. Bacterial causes of empyema in children, Australia, 2007-2009. Emerg Infect Dis 2011; 17:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/34\">",
"      Gonzalez BE, Hulten KG, Dishop MK, et al. Pulmonary manifestations in children with invasive community-acquired Staphylococcus aureus infection. Clin Infect Dis 2005; 41:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/35\">",
"      Alfaro C, Fergie J, Purcell K. Emergence of community-acquired methicillin-resistant Staphylococcus aureus in complicated parapneumonic effusions. Pediatr Infect Dis J 2005; 24:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/36\">",
"      Freitas M, Castelo A, Petty G, et al. Viridans streptococci causing community acquired pneumonia. Arch Dis Child 2006; 91:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/37\">",
"      Cowan MR, Primm PA, Scott SM, et al. Serious group A beta-hemolytic streptococcal infections complicating varicella. Ann Emerg Med 1994; 23:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/38\">",
"      Moses AE, Ziv A, Harari M, et al. Increased incidence and severity of Streptococcus pyogenes bacteremia in young children. Pediatr Infect Dis J 1995; 14:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/39\">",
"      Thaarup J, Ellermann-Eriksen S, Stjernholm J. Neonatal pleural empyema with group A Streptococcus. Acta Paediatr 1997; 86:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/40\">",
"      Fine NL, Smith LR, Sheedy PF. Frequency of pleural effusions in mycoplasma and viral pneumonias. N Engl J Med 1970; 283:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/41\">",
"      Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004; 113:701.",
"     </a>",
"    </li>",
"    <li>",
"     Rodgers BM, McGahren ED. Mediastinum and pleura. In: Principles and Practice of Pediatric Surgery, Oldham KT, Colombani PM, Foglia RP, Skinner MA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.929.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/43\">",
"      Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980; 69:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/44\">",
"      Potts DE, Taryle DA, Sahn SA. The glucose-pH relationship in parapneumonic effusions. Arch Intern Med 1978; 138:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/45\">",
"      Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax 2011; 66 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/46\">",
"      Mangete ED, Kombo BB, Legg-Jack TE. Thoracic empyema: a study of 56 patients. Arch Dis Child 1993; 69:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/47\">",
"      Sahn SA. The differential diagnosis of pleural effusions. West J Med 1982; 137:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/48\">",
"      Negus RA, Chachkes JS, Wrenn K. Tension hydrothorax and shock in a patient with a malignant pleural effusion. Am J Emerg Med 1990; 8:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/49\">",
"      Shin MS, Rahn NH 3rd, Ho KJ. Tension hydrothorax: roentgenographic characteristics and pathogenetic consideration. South Med J 1981; 74:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/50\">",
"      Prais D, Kuzmenko E, Amir J, Harel L. Association of hypoalbuminemia with the presence and size of pleural effusion in children with pneumonia. Pediatrics 2008; 121:e533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/51\">",
"      Wolach B, Morag H, Drucker M, Sadan N. Thrombocytosis after pneumonia with empyema and other bacterial infections in children. Pediatr Infect Dis J 1990; 9:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/52\">",
"      Jaff&eacute; A, Balfour-Lynn IM. Management of empyema in children. Pediatr Pulmonol 2005; 40:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/53\">",
"      Himelman RB, Callen PW. The prognostic value of loculations in parapneumonic pleural effusions. Chest 1986; 90:852.",
"     </a>",
"    </li>",
"    <li>",
"     Light, RW. Pleural diseases. Lea &amp; Febiger, Philadelphia1983.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/55\">",
"      Yang PC, Luh KT, Chang DB, et al. Value of sonography in determining the nature of pleural effusion: analysis of 320 cases. AJR Am J Roentgenol 1992; 159:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/56\">",
"      Eibenberger KL, Dock WI, Ammann ME, et al. Quantification of pleural effusions: sonography versus radiography. Radiology 1994; 191:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/57\">",
"      Merriam MA, Cronan JJ, Dorfman GS, et al. Radiographically guided percutaneous catheter drainage of pleural fluid collections. AJR Am J Roentgenol 1988; 151:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/58\">",
"      Hunnam GR, Flower CD. Radiologically-guided percutaneous catheter drainage of empyemas. Clin Radiol 1988; 39:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/59\">",
"      Stavas J, vanSonnenberg E, Casola G, Wittich GR. Percutaneous drainage of infected and noninfected thoracic fluid collections. J Thorac Imaging 1987; 2:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/60\">",
"      Ramnath RR, Heller RM, Ben-Ami T, et al. Implications of early sonographic evaluation of parapneumonic effusions in children with pneumonia. Pediatrics 1998; 101:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/61\">",
"      Donnelly LF, Klosterman LA. CT appearance of parapneumonic effusions in children: findings are not specific for empyema. AJR Am J Roentgenol 1997; 169:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/62\">",
"      Coren ME, Ng V, Rubens M, et al. The value of ultrafast computed tomography in the investigation of pediatric chest disease. Pediatr Pulmonol 1998; 26:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/63\">",
"      Calder A, Owens CM. Imaging of parapneumonic pleural effusions and empyema in children. Pediatr Radiol 2009; 39:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/64\">",
"      Boersma WG, L&ouml;wenberg A, Holloway Y, et al. Rapid detection of pneumococcal antigen in pleural fluid of patients with community acquired pneumonia. Thorax 1993; 48:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/65\">",
"      Le Monnier A, Carbonnelle E, Zahar JR, et al. Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. Clin Infect Dis 2006; 42:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/66\">",
"      Saglani S, Harris KA, Wallis C, Hartley JC. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. Arch Dis Child 2005; 90:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/67\">",
"      Eastham KM, Freeman R, Kearns AM, et al. Clinical features, aetiology and outcome of empyema in children in the north east of England. Thorax 2004; 59:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/68\">",
"      Menezes-Martins LF, Menezes-Martins JJ, Michaelsen VS, et al. Diagnosis of parapneumonic pleural effusion by polymerase chain reaction in children. J Pediatr Surg 2005; 40:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/69\">",
"      Gollomp K, Rankin SC, White C, et al. Broad-range bacterial polymerase chain reaction in the microbiologic diagnosis of complicated pneumonia. J Hosp Med 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/70\">",
"      Utine GE, Pinar A, Oz&ccedil;elik U, et al. Pleural fluid PCR method for detection of Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in pediatric parapneumonic effusions. Respiration 2008; 75:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/71\">",
"      Thomson AH, Hull J, Kumar MR, et al. Randomised trial of intrapleural urokinase in the treatment of childhood empyema. Thorax 2002; 57:343.",
"     </a>",
"    </li>",
"    <li>",
"     Mani CS, Murray DL. Acute pneumonia and its complications. In: Principles and Practice of Pediatric Infectious Diseases, 3rd ed, Long SS, Pickering LK, Prober CG (Eds), Churchill Livingstone, New York 2008. p.245.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/73\">",
"      Maskell NA, Butland RJ, Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 2003; 58 Suppl 2:ii8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/74\">",
"      Epstein DM, Kline LR, Albelda SM, Miller WT. Tuberculous pleural effusions. Chest 1987; 91:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/75\">",
"      Hallman JR, Geisinger KR. Cytology of fluids from pleural, peritoneal and pericardial cavities in children. A comprehensive survey. Acta Cytol 1994; 38:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/76\">",
"      Yam LT. Diagnostic significance of lymphocytes in pleural effusions. Ann Intern Med 1967; 66:972.",
"     </a>",
"    </li>",
"    <li>",
"     Panitch HB, Papastamelos C, Schidlow DV. Abnormalities of the pleural space. In: Pediatric Respiratory Medicine, Taussig LM, Landau LI (Eds), Mosby, St. Louis 1999. p.1184.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/78\">",
"      Dhawan A, Narang A, Singhi S. Hyponatraemia and the inappropriate ADH syndrome in pneumonia. Ann Trop Paediatr 1992; 12:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/34/9770/abstract/79\">",
"      Shann F, Germer S. Hyponatraemia associated with pneumonia or bacterial meningitis. Arch Dis Child 1985; 60:963.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6344 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-218.189.88.190-9543B823DE-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9770=[""].join("\n");
var outline_f9_34_9770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Stages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History and examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chest CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9786692\">",
"      Blood and sputum cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Pleural fluid analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Microbial analysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Bronchoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6344\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6344|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?9/48/9985\" title=\"diagnostic image 1\">",
"      Pleural effusion decubitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6344|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/59/15293\" title=\"table 1\">",
"      Pneumococcal vaccines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2585?source=related_link\">",
"      Airway foreign bodies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/3/38970?source=related_link\">",
"      Clinical features and diagnosis of community-acquired pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29209?source=related_link\">",
"      Clinical features of cerebral palsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/21/30042?source=related_link\">",
"      Epidemiology and clinical spectrum of methicillin-resistant Staphylococcus aureus infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21384?source=related_link\">",
"      Imaging of pleural effusions in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27882?source=related_link\">",
"      Management and prognosis of parapneumonic effusion and empyema in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36695?source=related_link\">",
"      Mechanisms of pleural liquid accumulation in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9735?source=related_link\">",
"      Mechanisms of pleural liquid turnover in the normal state",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/14/7402?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) conjugate vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13926?source=related_link\">",
"      Pneumococcal (Streptococcus pneumoniae) polysaccharide vaccines in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35001?source=related_link\">",
"      Pneumococcal pneumonia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17591?source=related_link\">",
"      Sputum cultures for the evaluation of bacterial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21046?source=related_link\">",
"      Systemic onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/35/12856?source=related_link\">",
"      Tuberculous pleural effusions in HIV-negative patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_34_9771="Neonatal behavioral syndrome";
var content_f9_34_9771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible neonatal behavioral outcomes associated with in-utero serotonin reuptake inhibitors (SRI) exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Tremors, jitteriness, shivering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased muscle tone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Feeding or digestive disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability or agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased reflexes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive crying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sleep disturbance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothermia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotonia or hypertonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seizures",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9771=[""].join("\n");
var outline_f9_34_9771=null;
var title_f9_34_9772="Neurologic sx D lactic acidosis";
var content_f9_34_9772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F73367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F73367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of neurologic symptoms and signs in 29 patients with D-lactic acidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Neurologic manifestation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered mental status*",
"       </td>",
"       <td>",
"        100",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dysarthria (slurred speech)",
"       </td>",
"       <td>",
"        65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ataxia",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gait disturbance",
"       </td>",
"       <td>",
"        34",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Weakness",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impaired motor coordination",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hostile, aggressive, abusive behavior",
"       </td>",
"       <td>",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to concentrate",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nystagmus",
"       </td>",
"       <td>",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hallucinations",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delirium, euphoria",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paranoid ideation",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irritability",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Excessive hunger",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partial ptosis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asterixis",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blurred vision",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * From mild drowsiness to coma",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Uribarri, J, Oh, MS, Carroll, HJ. Medicine 1998; 77:73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9772=[""].join("\n");
var outline_f9_34_9772=null;
var title_f9_34_9773="Dose response PEG rHuMGDF B";
var content_f9_34_9773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Response to thrombopoietin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 379px; background-image: url(data:image/gif;base64,R0lGODlhiAF7AcQAAP///4CAgAAAAEBAQMDAwPDw8BAQEDAwMNDQ0GBgYFBQUKCgoHBwcCAgIJCQkLCwsODg4AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACIAXsBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqM7EA4BDgUlBQStBAiksY8DArUHJQS1tQOyvYsPBQUNAgQkuQetsL7LicMQxgIGAwnPAAQB2Nna2cXM3nMOAgwlCAkBtLfW2+vnAd/vbwwCCSq1L9jw+WoKAg3YxQJ4BVBwLuA9d/oSltFVy53BB8MEKFDlAp/Ci4AsYty4RyPHj3Y8ghwZRyTJkzUg/7SiGMUkypcuFkTc1e2JS5g4UdAa4KCVg2EIndzMSXSEgZojHPCyGbSoUxLKTERtMvSpVSpVr6JkqGsplKxaSQ4YYODAWAP0WjYNW/SoCAZpv65lm3MegAIKvDKl+1SerrlMwPIFqZTnFMGDEwNBrFjf2Mdjx6lt/JLrLimMKWu2kXnzO6UKHhwG7Bmj31qiJ5ceKcAdXr1CSa9OKCA1A9hUZc+W82AgQwVIofAbcECAA8y6d78JYFlXXCh4o0lWrZxO9ObOoQxAgKAa1uTV0yBoMBM7sSe1B4BX0jl8mAUGfJuvpeBJ+cvU3bdh4HY+wycIKGBAA49Nt5d+bBRAXP81/ukSxQLB5YfgGeMlwFKD9jgxFVRyTZgGfMeRgKEAT7hVglIdemhGAiaSwI9/9TmxU08E/NRaiiqKUcABB3gHjX8RKiETQwMEyd56OVaBAFoqJDDfc0+oRABLOCbZxQICLMCCk81BaUh7VjLB4oYpEPAifUYSAmaYSEDAI5WfrMlmEQQwSYqccwrhgAFatqHeWzFWmSd0CTRA5hkQBEAgNmYhN6gUbg4AZxq5cIUkEXg+qkOdBiZIwAEJJDOapkLxSQcCrhy6RKak0oCXoXScZpCErRKBwAET1RFNNn0KWqsQD8R3hz9WsPprCwEYkJodt6Xq6LFB4HWAqnHQ0tX/s9D6MF6ueSygTa8HZssDfJfGYqy4I/CXJh3W4ucrujMo2KMft40lDrbw0lDhpH0cUK4Q50ILIiHC4BbYv/mOwOK6eLRrF60Jr7DjvILUOw2/qyIM75JefhSwpliCK0h0BnQaW8QtjHnITsVp/MPHc7p5AMaA1PaWwRmjXKadiAiLV6Dh6kzCniIbIuuyQQtdQKHUEgIa0kmjHCnNhPQGQKJNIwGzh8Ga3AxCAwB9stDJFq3IeQCcg2++0mZtSAMW7thxzhHfyi0kzOnC8BFbVxesy4EsEDbUY8ObLOFa9b2avG4Xpbhn21Jt1eOaDUwZ5Y2pq8mfADAgdm7Hyutj/yWJLhpAoxDnua8mlTIEeA+Y04VliJqwAqqoa+e5MCi9YZ17mBNLXolfZs595KMci4IWMmqnrmLIoxBTZAI4H8/m0gY0fglxDfBDe9Qeyix8JkvaMn4RsefE6TKvfGcl0bK4Ir/2mL7O19KwytJc9Umkf9LUvmCH2eiGoK69o3cBoN8Q/AeSsr2DeAowXv/s9w4z/WZvJGgbPJZ3Df5pjYLe4JJlJAgVXJ0vFNIjAPV+dxIRdokFf0sI97zHwpG0zjzrOpxCyieAmdUQJGcyz+dEwLiNtG9UdcHQCSJnmj6d4ocfGZEJLKcQ24XKTB7kGwh9IUUSaA4jN6wFCbVIlP8u3mVBHCmdelBxwgVusRdBxE6MVgeS7hTrjfFrUDFmdxL4XMt5I3HhCAGwu5OQJyA8Ax9KBOmc4FXmASSCCxRtGETgJA8mxPBXXiaJE+jhBFR585oLjpjB+R2ELdhTIEYc8D0YIIA5uLlhFkfAwFCIzz3WimUPcYcsPHpjfWW0zCxPkAtdSoMap7QK/IoCmQLRoJhSMQc6RHANdmiDc0XBnyobA80UZKia1sQGNnMCwKvcSjr6CgcyVGGQgRRkmGnzZSwMGJZhEOdGMnAYQHgBEfqcsJaZcCBbbAaATQJyIxqkSwD6FIAxGgGglbBbG1HiMHeBDiUxTIzFnKlI0yj/S2i9JEkRQcoCiD6CjiRdgUkbQcWUqlSemfjiZgpwCmwM0HoXEd1qHAZPN2KEYxO1yi552VFm8HE3/rqjQlSmHAb4w6acHIUjq8PTqIbikuFBlbMOOopw3NSlFYFpI1KpH+kRyaqcKCcuEbBRUeK0F8AEKw5W2odlynWuYj2ENu+qA7rm4VaS4mtf81q1ks2pALcJEOIIGAodzulFKhwiYz2R0DkZp0jNe5cmJPqo9BAgbGiFREYfxaIBZSm0juDPYoHHD8OidhEj/ZUdX5sIlJJqGpAUwDYXQ9huGaCVpEpPA0BFW6O16FfEQEtmi+oInWbrAMNwwAq5ugigoqtO/z36bXEDZxzBvjUSTIWXHy1aOEhMNV+HJItD0dfbN2A1YbWJ5HrrFwmvCi2TA+kpwNq7BrIKDZS1cOsEHaFWkrISiYuIK0kRuNuX8fcMdiUpBOfr00TsFawcXG55CwHYoB4rhdPVLCDoedcZdpe6enAsX3noQxTfobLeJaWL68BZ7wJgLEoVxGhtrOEZy0G1NvZiQCKzXTXENsg3PisRwBnOce7BtkhWyV2mRKdwZsPJvgUuknF1F7gV2QwyRbKIutHjg+1hYqMTswi0W1DJfpfGaPFwSp3Eo9P6GA2eVPMJlobOL4MhvHr2gl+RcN5ASyUvRL7zGOpE4SCXR79BGP90Eexr6Hq4+aJwuHClU6AAAZsZDgXe9AlYxFERn0HBotaJkk1dhginGgyS7sGrGozkBRjI1n6eQodfrdKnihPSvF3DjnmNgrytmrlfUDGxU6CoawLbwWiA8bJRgOsRVJvVXKjxtMkQ6xqQa9tn6PYMgAxuM4gbBs4tdxnO7QIoq1sM7GZBS9/N7QfrIMz0rrcX0JxvNMR7iXHut7/t7W07CzzcBJ8BoA++7oSj+00MT8O/rZHIiJvb4S2gtMUHXgVNbxzhVAj1xxs+BVSP/OJScPXJUf6EWa98DYPe9cvV4NdhzxzkgfnozWGOcWnvHOdI0HYKFlDJr/58w0T4tsT/4qiLux091y4g9woqypVnPz3YRUi3CrDkH6NfnYy2gtv5iuOfdHwd2TiY9wrMeHZMAwHfLGB72yfLA37HQO5zH/APrCuD+zTH7Hl/cw7yLAOuz8frgcf60Iu+goXncz5WT/wNhnIdyzh9BIV2FdP9KXm6j4Dqx6ZmxW9A9N8gvvMF8NYC4MSKrYb0BIY3D7g03vknFGeaPyKvCm5C9vmkw+O1bwIk68MPpB2DqC9FgRRFHvxV3Yg5TcnFMavBZGtiWQQjMnnzA/N8fIqgHAVJR/XZcX0AjMhU249COMYhDy2bn0RhRYHfLZO99EOqHwRwhvkFQpCdJHOKDXJ69lcE/0PSAH3yEBFxebsnG6D3RwMIB5S3eRIhZw/YBVlRek0ngBU4BhO3gZ/mgYHQgSCodyP4ByJYgg+FcSjoPivYByfYgvsFg3zwgjIIbTWYBzR4gzyQgzo4WD14Bzz4g5OngkJIgkVYEkR4hCmohHIQhEwYA074hP8nhWwQhVRYUkl4hTaohTSXhVy4g174hT4ohhxHhkBnhvqGhiSnhmnIhvAWhm4oA1bohnPIhnWohneIhnlohntIhn0ohn/4hYHIhYOohYV4hYdIhYl4g+N3ZWtkZZAYiZI4iZRYiZZ4iZiYiZq4iZzYiZ7IDhjUBo34a5Q4Fk32iOtgitugiqmIiv+s+ImliIqb+IqRSIuneIu46GytqIuweIm2iImhGBKXMhTEOBc34RErdS6ZgRjFuIAmYBLImISLiHTMJhvNWALH2BTJuEXLiCTXWGzGGI4k4FfT6HbJB47V+IykEY0fOIQwwIzWqBvQKI60JI1wWIXDGI/piI3rqI0qqIzlAo/7iI78qI7jaI+ewBjfaJAFeQLs6Hkz0I3xR5AUWY8MKQLkeI9r0AovwJEo4JHEFCEgiQtIsVIjaQMnuQIp+ZFpspIjkJIwWZJJ6JKrUY5rGGg22YZ6lpMcqJHVwZNvWGlAGQZDyRFFmWw+qRw0CQ9LGYdO+ZRQGZVSOZVUWZVWeZX/UqV6/MIKafZLtPZcAdFDJmBBSflXsGRjw1dQBDUCf5EPucRj3WeM3ldBsyJY0Jc2c4mReflLdclX69c5JzaOe8kM3SRYEIB/+jcrKjQPwfgJCKBOVCZYBXiAS8EV8KBPWJmZmrmZnNmZnvmZoBmaojmanCBJCDAAGogDp5maTnmY7pALBAebrRkAxZAoxbA0a1QTzPEMstkbsPAA0yASC6UUCFEA5xAa6oAAEJJB1MMP7iA4gwMAvQMA3kKBGyibslkccOF93UNNrZEL9ABJ/jIMJSAdNHQA8VEcrxQNc6mdTuIOnaYoAgABfDQgVIid32kXsimdBJUL/OFDtPAM/rRQnrxQAAGBAAHRUK3BHFCDoPQgm4kyAMMwJWUBSe73g/hJmzeynyzyktFgAAagCgOaZASKfUWSoP/AHMGRoRBQFgvgJMVAZwJgndcZEAQgDwFgoA1wozdioNPhn+FQHzjaT+WJDE5yHCAKIQ7gLWiDeQPCoxoKHLRQDJVyaT2YC/Z0I35EC+4QDt4hm7SQCrRwSOUJovcCAAFSCw3QG01qbQYQlu7gJGWBNsOwWhialxBiQaJBICtAnwQAH4C3f0Kgo1q4nwqjpq5BmyvAQwqwIX3pA+FQlqQ5qZRaqZZ6qZiaqZq6qZzaqZ76qaAaqqI6qqRaqqZ6qqi6BiEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The fold increase in platelet count on day 14 is shown here versus the logarithm of the administered dose of thrombopoietin. The platelet counts returned to baseline values upon discontinuation of therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Harker, LA, Marzec, UM, Hunt, P, et al, Blood 1996; 88:511.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9773=[""].join("\n");
var outline_f9_34_9773=null;
var title_f9_34_9774="Derivation Doppler indices";
var content_f9_34_9774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73657&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler indices derived from the maximum frequency shift envelope",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 320px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     S: peak systolic frequency shift; D: end diastolic freqency shift; and A: temporal average frequency shift over one cardiac cycle.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from Maulik, D, Yarlagadda, P, Youngblood, JP, Willoughby, L. Componants of variability of umbilical arterial Doppler velocimetry: a prospective analysis. Am J Obstet Gynecol, 1989; 160:1406.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9774=[""].join("\n");
var outline_f9_34_9774=null;
var title_f9_34_9775="Wound eversion A";
var content_f9_34_9775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F60681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F60681&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Needle insertion for eversion technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    For proper healing, the edges of the wound must be everted. To accomplish this, the needle should penetrate the skin at a 90 degree angle to its surface.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_34_9775=[""].join("\n");
var outline_f9_34_9775=null;
